Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter
about
Plasma membrane transporters in modern liver pharmacologyDeterminants of Cytochrome P450 2C8 Substrate Binding: STRUCTURES OF COMPLEXES WITH MONTELUKAST, TROGLITAZONE, FELODIPINE, AND 9-CIS-RETINOIC ACIDExamination of 209 drugs for inhibition of cytochrome P450 2C8Xenobiotic, bile acid, and cholesterol transporters: function and regulation.Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic studyThe role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.Impact of OATP transporters on pharmacokinetics.The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.Cerivastatin, genetic variants, and the risk of rhabdomyolysis.CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinideElucidating mechanisms of drug-induced toxicity.Combinatorial pharmacogenetics.In Vitro Metabolism of Montelukast by Cytochrome P450s and UDP-GlucuronosyltransferasesStatin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.Interaction between Red Yeast Rice and CYP450 Enzymes/P-Glycoprotein and Its Implication for the Clinical Pharmacokinetics of LovastatinNo significant effect of SLCO1B1 polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone.Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Can pharmacogenetics help rescue drugs withdrawn from the market?Transporter-mediated drug interactions: clinical implications and in vitro assessment.Transporter-mediated uptake into cellular compartments.Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges.Role of OATP transporters in the disposition of drugs.Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions.A screening study of drug-drug interactions in cerivastatin users: an adverse effect of clopidogrelInterindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABCB1) protein expression: quantification by liquid chromatography tandem mass spectroscopy and influence of genotype, age, and sexRhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Effects of pharmaceuticals and other active chemicals at biological targets: mechanisms, interactions, and integration into PB-PK/PD models.Importance of drug transporters in pharmacokinetics and drug safety.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Update information on drug metabolism systems--2009, part I.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Pharmacogenomics and adverse drug reactions: the case of statins.
P2860
Q26829263-652D8605-A08B-45CF-91A7-6F5291F53DE2Q27650327-AB5ABF9B-7E58-4716-A9BA-070F09DCC74BQ28298519-3CB75BD0-3C8D-4786-B9DB-B1A41567F212Q33714593-573CC3C1-7877-4623-92EC-A0D05B09B5DDQ33746585-90EF14FB-46C2-4C14-86D9-F6F2EC233E43Q33967634-3A52F87B-8B86-4776-A9E6-93A893E3F043Q34065294-3B156B8B-333E-452B-B869-3D4850EAD497Q34561039-A4728C8B-BD94-4FCC-90E8-12B2DED8CC12Q34612244-EF539F87-6E80-4508-A809-144B238AE5F2Q34613443-D6154942-27BA-4BDB-B13F-E0D12D189739Q34792178-6206CAC5-8D17-48CF-828B-76ECF008DF4AQ35718619-DAFAF627-E164-4C7B-859F-0286FF4434F0Q35826894-054BD1FF-3EDB-4801-A8E3-B63DC419D6C9Q35827146-964B0BA1-557D-4B67-8EF3-76F6413A404BQ35827882-E498AACC-E78E-4B69-A775-64BF14BDFACDQ36111915-1608093C-619D-493B-9789-136CEBEFF06AQ36303810-4FD4743C-1DCF-442B-80EE-57AC4172070CQ36316466-40775942-AA5B-4E49-AE13-7CA31061C409Q36349758-83A844F2-B4D2-41E2-82E4-77695A86DCDBQ36444037-8CB5A9C7-6672-4D65-9C24-33DB1ADD1415Q36536042-F26D70B2-AD52-43AD-B405-67D7D4CFC657Q36544966-0F845D65-B85A-4486-B942-8F424BF1BDDAQ36562502-CF0CE8A2-D711-4647-99B5-7E3B7B032170Q36596713-CBF41090-A39B-48D7-9640-192E9DDF8C7EQ36725222-50E2CA5E-E097-4BB6-B2A0-25B89B621217Q36985076-5E22BB96-FFB9-45F8-B221-E75E2FDC8A8DQ36986507-D2338488-ADAD-4307-A4BF-0AF9DB8D2191Q37074085-EE9BF83D-2907-471D-98A7-30917EBAE71EQ37196109-51949EF5-FB89-4E0E-BE12-9637D96597F5Q37237438-81D1640C-4346-4DB6-B08A-44B3A785CA02Q37316562-A6170949-8A42-4787-9414-3DC64F4AF48AQ37422685-33E68D2A-6C67-4FA7-A68E-8A9F2580608FQ37473376-5674BF45-3D53-46C8-89E9-EBDC92AD32A3Q37481450-8B369E99-5F56-40B2-870D-98902DDB9BEAQ37521097-5A2105E5-9383-4C6B-9E62-5B8AF7FD06B1Q37658682-A5761AB1-B7AF-4449-97B5-AB277ADC220CQ37680968-C9A6C439-4757-417F-86BB-62FBD2162968Q37716030-5F91BF1B-C8E3-4596-8943-A57851DD7D1FQ37855801-ACA1FEF2-DBE9-4558-B54E-C8439286C449Q37875115-C45A04AE-E253-4ADF-8883-EDD9B116B22B
P2860
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug inter
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@ast
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@en
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2
@nl
type
label
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@ast
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@en
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2
@nl
prefLabel
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@ast
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@en
Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2
@nl
P2093
P356
P1476
Gemfibrozil and its glucuronid ...... cally relevant drug-drug inter
@en
P2093
Hitoshi Sato
Masaru Hirano
Yoshihisa Shitara
Yuichi Sugiyama
P304
P356
10.1124/JPET.104.068536
P407
P577
2004-06-11T00:00:00Z